Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators
- 27 March 2024
- journal article
- research article
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (5) , 846-853
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Impact of ventricular arrhythmia management on suboptimal biventricular pacing in cardiac resynchronization therapyJournal of Interventional Cardiac Electrophysiology, 2022
- Class IC antiarrhythmic drugs for suspected premature ventricular contraction–induced cardiomyopathyHeart Rhythm, 2018
- Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathyHeart Rhythm, 2017
- Ventricular Ectopy as a Predictor of Heart Failure and DeathJACC, 2015
- Flecainide Use in Children with Cardiomyopathy or Structural Heart DiseasePediatric Cardiology, 2014
- Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: A single-center retrospective studyHeart Rhythm, 2014
- Reversal of outflow tract ventricular premature depolarization–induced cardiomyopathy with ablation: Effect of residual arrhythmia burden and preexisting cardiomyopathy on outcomeHeart Rhythm, 2011
- Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fractionHeart Rhythm, 2009
- Mortality Following Ventricular Arrhythmia Suppression by Encainide, Flecainide, and Moricizine After Myocardial InfarctionJAMA, 1993
- Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression TrialThe American Journal of Cardiology, 1991